← boardnext 2026-11
APTOF
Aptose Biosciences Inc.distress 4/10 · elevated risk$1.69+1%today-9% from 52w high
Lead: Leukemia · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$3M
Runway
0.1 yrs
Shares 1y
0%
Price & events
+5.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.9%
1D
+10.5%
1W
+7.0%
1M
+0.0%
3M
+9.8%
6M
+90.6%
1Y
—
2Y
—
5Y
-76.1%
All
Overview
- Market Cap
- $4.31M
- Volume
- 636
- 52 Week Range
- $0.80 – $1.85
- Total Shares
- 2.55M
- Float Shares
- 320.61K
- Short %
- 2.60%
- % Held by Insiders
- 107.43%
- % Held by Institutions
- 3.91%
- RVOL
- 0.28x
- Beta
- 0.34
Pipeline stages · 1 programs
Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11 Estimated 50% readout ~2026-12-16 | Phase 1/2 | Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous Infusion | Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome With Excess Blasts-2, Chronic Myelomonocytic Leukemia | — | recruiting |
Catalyst news & presentations · 1
- 2026-06-30partnershiptuspetinib · Hanmi Purchaser completed acquisition of Aptose; shareholders received C$2.41/share.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-03-28HC Wainwright & Co.Buy
Competitors — Leukemia
- JNJJOHNSON & JOHNSON$617.4B · D0
- ABBVAbbVie Inc.$451.1B · D2
- MRKMerck & Co., Inc.$318.8B · D3
- NVSEFNOVARTIS AG$292.0B · D3
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NRIXNurix Therapeutics, Inc.$2.4B · D6
- SNDXSyndax Pharmaceuticals Inc$1.9B · D5
- KURAKura Oncology, Inc.$917M · D5
- INABIN8BIO, INC.$12M · D7
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-20What's Going On With Aptose Biosciences Inc Stock Monday? - Wealth Awesome
- 2026-07-14What's Going On With Aptose Biosciences Inc Stock Monday? - Wealth Awesome
- 2026-07-06News On Aptose Biosciences Inc. (APS.T) Now Under 128940.SE - Moomoo
- 2026-07-02Former Aptose Biosciences (APTOF) director exits in Hammi acquisition - Stock Titan
- 2026-07-01Aptose Biosciences (APTOF) former CMO disposes all shares and options in Hammi acquisition - Stock Titan
- 2026-07-01Former Aptose Biosciences (OTC: APTOF) director relinquishes shares in Hammi acquisition - Stock Titan
- 2026-07-01[15-12G] Aptose Biosciences Inc. SEC Filing - Stock Titan
- 2026-07-01Aptose Biosciences (APTOF) ex-director disposes options as Hammi acquisition closes - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.